Future Science OA (Feb 2020)

Prognostic factors for patients treated with abiraterone

  • Cecília M Alvim,
  • André Mansinho,
  • Rita S Paiva,
  • Raquel Brás,
  • Patrícia M Semedo,
  • Soraia Lobo-Martins,
  • Carolina B da Ponte,
  • Daniela Macedo,
  • Leonor Ribeiro,
  • José P dos Reis,
  • Isabel Fernandes,
  • Luís Costa

DOI
https://doi.org/10.2144/fsoa-2019-0079
Journal volume & issue
Vol. 6, no. 2

Abstract

Read online

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.

Keywords